Trial Profile
Prospective, Open-label, Comparative, Multicenter Study of Voriconazole Compared to Itraconazole for the Primary Prophylaxis of Invasive Fungal Infections (IFI) in Subjects with Allogeneic Hematopoietic Stem Cell Transplants (HSCT)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Voriconazole (Primary) ; Voriconazole (Primary) ; Itraconazole; Itraconazole
- Indications Mycoses
- Focus Adverse reactions; Therapeutic Use
- Acronyms IMPROVIT
- Sponsors Pfizer
- 07 Jun 2011 New trial record
- 25 May 2011 Economic results for the first 100 days presented at the International Meeting of the International Society for Pharmacoeconomics and Outcomes Research.
- 10 May 2011 Economic results after the first 100 days presented at the 21st European Congress of Clinical Microbiology and Infectious Diseases and the 27th International Congress of Chemotherapy.